publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
HER3-DXd
Cost of early progression: Patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer
T-DXd
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: A plain language summary of the DESTINY-Lung01 study
HER3-DXd
Patritumab deruxtecan in HER2-negative breast cancer: Part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Edoxaban
Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: A Cancer-VTE registry subanalysis
Edoxaban
Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: Post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial
T-DXd
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Edoxaban
R2-CHA2DS2-VASc score for cardiovascular event prediction after bioprosthetic valve replacement: Subanalysis from the BPV-AF registry
Valemetostat
A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer
Dato-DXd, DS-1103, Other/Multi
Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates
Edoxaban
Application of the win ratio method in the ENGAGE AF-TIMI 48 trial comparing edoxaban with warfarin in patients with atrial fibrillation